White House Adds Praluent to TrumpRx Drug Discount Program
Synopsis
The White House announced the addition of Praluent, a powerful cholesterol medication, to the TrumpRx drug discount initiative on July 29, 2026, continuing the Trump administration's incremental push to lower prescription drug costs for American patients.
Key Takeaways
Praluent , a PCSK9-inhibitor cholesterol drug, has been added to the TrumpRx prescription discount program.
The White House made the announcement on July 29, 2026 , calling it 'another win' for the initiative.
TrumpRx operates through voluntary discount arrangements with drug manufacturers rather than statutory price controls.
The program builds on the 2018 American Patients First blueprint and 2020 executive orders on Medicare drug pricing.
Key beneficiaries include Medicare enrollees and patients who cannot afford high-cost brand-name medications out of pocket.
A cholesterol-fighting drug used by millions of Americans has just joined the White House's flagship prescription savings initiative — and the administration is framing it as proof that TrumpRx is only getting started.
The White House announced on Wednesday, July 29, 2026, that Praluent, a powerful cholesterol medication, has been added to the TrumpRx program, describing the move as 'another win' in the administration's push to deliver prescription drug savings to American patients.
What Praluent Is and Why It Matters
Praluent belongs to a class of injectable cholesterol-lowering drugs known as PCSK9 inhibitors — among the most potent options available for patients who cannot control LDL cholesterol through statins alone. These medications have historically carried steep price tags, making them inaccessible for many patients without robust insurance coverage. Their inclusion in a discount initiative directly targets one of the more stubborn affordability gaps in cardiovascular care.
TrumpRx: The Program Behind the Announcement
TrumpRx is a Trump administration initiative designed to expand access to discounted prescription medications, operating through voluntary discount arrangements with manufacturers rather than statutory price controls. The program reflects a broader philosophy the administration has pursued since 2018, when it released the American Patients First blueprint — a policy framework targeting prescription drug pricing through transparency requirements and market-based tools.
In 2020, the administration followed up with executive orders aimed at international reference pricing for certain Medicare drugs, anchoring U.S. prices closer to what other countries pay. TrumpRx continues that incremental approach: expand the basket of discounted drugs, report the savings, and build political momentum around each addition.
Savings Claims and What Comes Next
The White House has positioned the program around a narrative of accumulating wins for ordinary Americans — with the administration stating it remains 'focused on delivering even more savings.' The key constituencies are Medicare beneficiaries and uninsured or underinsured patients who bear the highest out-of-pocket burden for brand-name drugs.
Watch for further announcements on which medications are added to TrumpRx next, and whether the administration releases updated aggregate savings figures to sustain the program's political momentum heading deeper into 2026.
One drug at a time, the White House is building a list — and betting that list becomes a legacy.
Point of View
But limited in scope compared to statutory negotiation authority. For the administration, the program serves a dual purpose: delivering tangible, nameable benefits to voters while sidestepping the legislative battles that broader reform would require. The real test will be whether the pace of additions and the scale of reported savings can sustain public attention through the remainder of 2026.
NationPress
29 Jul 2026
Frequently Asked Questions
What is Praluent used for?
Praluent is a PCSK9-inhibitor injection used to lower LDL cholesterol, typically prescribed to patients who cannot adequately control cholesterol levels through statin medications alone.
How does TrumpRx lower drug prices?
TrumpRx works through voluntary discount arrangements with pharmaceutical manufacturers rather than government-mandated price controls, offering reduced prices on a growing list of medications.
Who benefits from the TrumpRx program?
The primary beneficiaries are Medicare enrollees and uninsured or underinsured American patients who face the highest out-of-pocket costs for brand-name prescription drugs.
What is the history of Trump administration drug pricing policy?
The Trump administration released the American Patients First blueprint in 2018 and issued executive orders in 2020 on international reference pricing for Medicare drugs; TrumpRx is the latest extension of that policy lineage.
